It should not be underestimated, however, a recent report by Miller JS and colleague describing an in vivo detrimental effect of the systemic administration of engineered IL-15 (IL-15/N-803) in relapsed/refractory acute myeloid leukemia (AML) patients receiving haplo NK cells [159]. This evidence concerns the gene IL15 and acute myeloid leukemia.